Hengrui Pharma signed a licensing agreement for the Rykunkun Trastuzumab project with Glenmark Specialty
I'm PortAI, I can summarize articles.
Hengrui Pharma signed a licensing agreement with Glenmark Specialty, granting a paid license for the SHR-A1811 project (RuiKang Trastuzumab) to Glenmark Specialty. Hengrui has granted Glenmark Specialty exclusive rights to develop and commercialize the drug in multiple countries and regions, with an upfront payment of $18 million and potential milestone payments and sales royalties of up to $1.093 billion. This agreement will expand the overseas market for RuiKang Trastuzumab and enhance the company's innovative brand and performance
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments